Should you stop peptides before surgery?

You have a knee scope scheduled for next month. You're four weeks into a BPC-157 cycle, deep in your morning Ipamorelin protocol, and quietly hoping the peptides will speed your post-op recovery. Do you tell the surgeon? Stop the peptides? Push through? This is one of the most common practical questions in the strength-peptide community, and the answers are surprisingly unsettled because the clinical guidance for these compounds is essentially nonexistent in formal perioperative literature.

This post walks through the practical framework most surgeons and anesthesiologists would apply if you told them what you were using — and the practical realities of how to manage the transition cleanly.

The default position: stop most peptides 1–2 weeks before surgery

Without specific evidence to the contrary, the conservative position for any unapproved compound before surgery is stop it. Surgery and anesthesia involve enough variables (anticoagulation, drug interactions, fluid balance, immune response, healing) that you don't want to introduce unknowns. For strength peptides specifically:

• 2 weeks before surgery for most compounds is the standard cushion
• 1 week before for shorter-acting compounds with cleaner profiles
• 4+ weeks before for compounds with long half-lives or significant systemic effects

This isn't because peptides are known to be dangerous around surgery — it's because we don't have the data to know they're safe, and the cost of being conservative is small (a brief cycle pause), while the cost of an unexpected interaction can be significant.

For broader context on cycle management see tapering vs cold-stopping a peptide cycle and when to stop a peptide cycle early.

The per-peptide guide

The longer end of each range is appropriate for:

• Major surgery (vs. minor outpatient procedures)
• Cardiac, vascular, or neurosurgical procedures
• Surgeries with high bleeding risk
• Users on multiple peptides simultaneously

For routine outpatient procedures (dental, skin, simple orthopedic) the shorter end is usually fine.

Why the angiogenic concern with BPC-157 and TB-500

The most-cited concern for the recovery peptides is their pro-angiogenic effect — promoting new blood vessel formation in healing tissues. In normal recovery, this is the feature, not the bug. Around surgery, it's worth thinking about for two reasons:

1. Bleeding dynamics during surgery — increased vascularity in tissues being operated on could theoretically increase intraoperative bleeding. The clinical relevance for the doses used in strength-peptide community is not established, but surgeons asked about this generally prefer no exogenous angiogenic input during the surgical window.

2. Post-surgical healing — interestingly, resuming BPC-157 after surgery is sometimes recommended (informally) by orthopedic surgeons for tendon and ligament procedures. The compound shines in the healing phase, not the cutting phase.

The "stop before, resume after" pattern is the practical norm in the community. See BPC-157 for post-surgery and recovery stack: BPC-157 + TB-500.

The disclosure question

A separate, equally important question: do you tell your surgical team you've been using peptides?

The honest answer is yes — and to do it during the pre-op visit, not the day of surgery. Reasons:

• Anesthesia planning can be affected by anything that influences glucose, blood pressure, or fluid balance. GH-axis peptides do all three in subtle ways.
• Drug interactions with anesthesia medications and perioperative antibiotics aren't well-characterized for most peptides, and your anesthesiologist needs to know what's in the system.
• Bleeding-time medications (aspirin, fish oil, NSAIDs) typically get stopped pre-op for the same reason peptides should be — your surgical team is already familiar with this category of management.

The unhelpful reality is that most physicians will not be familiar with the specific peptides you're using. Your conversation may include:

• Explaining what BPC-157 is (be ready)
• A frustrated "stop everything" recommendation that's more conservative than needed
• A surgeon who genuinely doesn't care and tells you to use your judgment
• A rare physician who knows the literature and has a thoughtful opinion

All of these are normal. The disclosure itself is the important part. For the broader doctor-disclosure framing see should I tell my doctor I'm using peptides?.

Special cases

A few situations warrant longer stops or extra care:

Cardiac surgery. Stop all peptides 4 weeks before. Cardiac anesthesia is more sensitive to fluid balance and glucose; GH-axis peptides can affect both subtly. Tesamorelin has cardiac considerations (it raises IGF-1, which has cardiac muscle implications); be especially conservative.

Bariatric surgery. Stop GLP-1-related peptides per your bariatric team's protocol. If you're on a GLP-1 + peptide stack (see semaglutide + peptide stack), discuss the full regimen with the team — they may want you off both compounds for 2+ weeks.

Orthopedic surgery with planned BPC-157/TB-500 recovery use. Many users plan to resume recovery peptides post-op. Discuss timing with the surgeon — typical pattern is to resume 1–2 weeks post-surgery once initial wound healing is underway and infection risk is past.

Dental implants and bone-related procedures. GH-axis peptides may theoretically affect bone metabolism. Stop at least 2 weeks before for cleaner perioperative course; resume after osseointegration is underway (usually 6+ weeks post).

Emergency surgery. You don't get a choice. Tell the team immediately what you've been using. Honest disclosure is much better than discovery during a complication workup.

What about IGF-1 around surgery?

IGF-1 LR3 deserves its own section because the interaction concerns are more specific.

Why it matters: IGF-1 affects glucose metabolism (potentially hypoglycemia), cellular proliferation (theoretical wound-healing modulation), and is taken up by many tissue types. Anesthesia and surgery involve glucose management, and an exogenous IGF-1 source complicates that.

Practical guidance: Stop IGF-1 LR3 at least 2 weeks before surgery, 4 weeks for major procedures. Resume after wound healing is established and you're off any perioperative antibiotics — typically 2–3 weeks post for routine surgery, longer for major procedures.

For protocol detail see IGF-1 LR3 side effects and hypoglycemia on IGF-1 LR3.

What to track during the off-cycle window

Stopping peptides 1–4 weeks before surgery is also a useful diagnostic moment. Some markers worth checking:

• Fasting glucose / HbA1c — confirms metabolic state is at baseline pre-surgery
• IGF-1 — should fall back toward baseline if you were on GH-axis peptides
• CBC — basic blood work the surgical team will likely order anyway
• Inflammatory markers (CRP) — should be at baseline; rising CRP before surgery is worth investigating

For the broader monitoring frame see baseline labs before a cycle.

Resuming peptides after surgery

Once you're past the acute surgical window and your surgeon has cleared you for activity, the question of resuming peptides comes up.

A practical timeline:

• Week 1 post-op: No peptides. Focus on wound healing, infection prevention, mobility.
• Week 2–3: BPC-157 may be reasonable to restart for tissue recovery, with surgeon awareness. Especially relevant for orthopedic surgery.
• Week 4+: Other peptides can be reintroduced based on the original goal and the type of surgery.

This isn't a blanket rule. The pattern depends on the surgery, your recovery, any complications, and your surgeon's input.

The honest framing

The strength-peptide community has built up enough informal practice around perioperative management that a reasonable default — stop 1–2 weeks before, disclose to the team, resume cautiously after wound healing — is clear. The data to anchor more precise guidance doesn't exist for most of these compounds in the surgical context, and probably won't anytime soon given the regulatory status.

The most important things you can do: tell your surgical team, stop with enough cushion, and don't try to be clever about it. A clean, well-documented perioperative course is much better than a complication that's harder to manage because the team didn't know what you were on.

Related reading

• BPC-157 for post-surgery
• Recovery stack: BPC-157 + TB-500
• When to stop a peptide cycle early
• Should I tell my doctor I'm using peptides?
• Tapering vs cold-stopping a peptide cycle